Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00038077 |
The purpose of this study is to determine whether treatment with Toprol-XL for 12 months in asymptomatic heart failure subjects will improve their heart structure and thus prevent the progression to symptomatic disease.
Condition | Intervention | Phase |
---|---|---|
Heart Failure, Congestive |
Drug: Toprol-XL 50 mg Drug: Toprol-XL 200 mg Drug: Placebo |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Safety/Efficacy Study |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 276, USMET0002 |
Study First Received: | May 28, 2002 |
Last Updated: | June 10, 2009 |
ClinicalTrials.gov Identifier: | NCT00038077 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Neurotransmitter Agents Heart Failure Heart Diseases Adrenergic Agents Metoprolol succinate Adrenergic beta-Antagonists |
Adrenergic Antagonists Peripheral Nervous System Agents Cardiovascular Agents Anti-Arrhythmia Agents Antihypertensive Agents Metoprolol |
Sympatholytics Heart Failure Neurotransmitter Agents Heart Diseases Adrenergic Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Cardiovascular Agents Antihypertensive Agents Metoprolol |
Pharmacologic Actions Autonomic Agents Therapeutic Uses Metoprolol succinate Adrenergic beta-Antagonists Cardiovascular Diseases Adrenergic Antagonists Peripheral Nervous System Agents Anti-Arrhythmia Agents |